How Is Geographic Atrophy Treated?

How Is Geographic Atrophy Treated?

Geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD), cannot be reversed, but new treatments can slow its progression and preserve remaining vision for longer.(1–4) The main evidence‑based options today are intravitreal complement‑inhibitor injections (pegcetacoplan and avacincaptad pegol), AREDS2 nutritional supplements in eligible patients, and comprehensive low‑vision rehabilitation and lifestyle management.(1–4)

Key Facts at a Glance

• Geographic atrophy (GA) involves irreversible loss of retinal pigment epithelium (RPE) and photoreceptors in the macula and is a major cause of central vision loss worldwide.(1,5)
• Two intravitreal complement inhibitors—pegcetacoplan (C3 inhibitor) and avacincaptad pegol (C5 inhibitor)—are now approved in several countries to slow GA lesion growth by about 14–30% in phase 3 trials.(1–4,6–8)
• These drugs do not restore lost tissue; they aim to delay enlargement of atrophic areas and encroachment on the fovea.(1–4,6–8)
• AREDS/AREDS2 nutritional supplements may also slow GA expansion, particularly when lesions are extrafoveal.(9)
• Low‑vision rehabilitation and assistive devices significantly improve function and quality of life in people with GA‑related vision loss.(10)
• Careful monitoring is needed because complement‑inhibitor therapy modestly increases the risk of neovascular (wet) AMD, which remains treatable with anti‑VEGF injections.(1–4,6–8)

Pathophysiology and Mechanism

Geographic atrophy represents the end stage of non‑exudative AMD, characterized by sharply demarcated areas of RPE and photoreceptor loss in the macula.(5,11) Histologic and genetic studies implicate chronic complement activation and inflammation at the RPE–Bruch’s membrane–choriocapillaris interface as key drivers.(5,11–13) Variants in complement factor H, C3, CFI, and other complement genes increase susceptibility, and complement fragments such as C3a, C5a, and membrane‑attack complex are abundant in drusen and atrophic tissues.(11–13)

Over years, RPE cells accumulate oxidative damage and lipofuscin, while Bruch’s membrane thickens and choriocapillaris capillaries are lost.(11–13) When the RPE and overlying photoreceptors die, they leave areas of bare choroid visible as GA lesions on fundus imaging and optical coherence tomography (OCT).(5,11) Because these cells do not regenerate, treatment focuses on slowing further cell loss rather than restoring destroyed tissue.

Complement inhibitors target central components of the complement cascade to reduce ongoing inflammatory injury. Pegcetacoplan binds C3, preventing formation of downstream activation fragments, whereas avacincaptad pegol binds C5, inhibiting generation of C5a and membrane‑attack complex.(1–4,6–8,12–14) By dampening complement‑mediated damage, these drugs modestly slow the radial expansion of GA lesions.

How Geographic Atrophy and Its Treatment Affect Daily Vision

GA typically begins outside the fovea, so people may maintain good central acuity early on while noticing difficulty reading, reduced contrast, and problems with low‑light tasks.(5,11,15) As lesions enlarge and involve the fovea, patients develop central scotomas—blind spots in the centre of vision—that make reading, recognizing faces, and driving increasingly challenging.(5,11,15) Peripheral vision often remains intact, but everyday activities can become slow and tiring, especially under dim lighting.

Complement‑inhibitor treatment does not make vision sharper in the short term. Instead, by slowing GA lesion growth, these drugs are intended to delay the time until central vision is significantly affected, effectively “buying time” before foveal involvement.(1–4,6–8) Low‑vision rehabilitation—using magnifiers, high‑contrast lighting, electronic readers, and training in eccentric viewing—helps patients adapt to central scotomas and make better use of remaining peripheral retina.(10,15) Combining disease‑modifying therapy with rehabilitation and environmental adaptations offers the best chance to preserve independence.

Clinical Evidence and Risk Mitigation

Complement inhibitors

Randomized phase 3 trials have established the efficacy of complement inhibition:

• Pegcetacoplan (C3 inhibitor): In the OAKS and DERBY trials, monthly or every‑other‑month pegcetacoplan injections reduced GA lesion growth by 17–22% at 24 months compared with sham, with greater effects observed when treatment was started earlier.(2,4,6,8,14) Extension data suggest additional slowing with continued therapy.(4,6)
• Avacincaptad pegol (C5 inhibitor): In GATHER1 and GATHER2, monthly avacincaptad pegol achieved approximately 27–35% reduction in GA growth at 12–18 months in some analyses using observed values and about 14–19% reduction at 24 months in square‑root–transformed analyses, compared with sham.(3,7,8)

Both agents increased rates of conversion to neovascular AMD relative to sham, with cumulative incidence in the range of 7–13% over 24 months depending on dose and regimen.(2–4,6–8,14) Neovascular AMD remains treatable with anti‑VEGF injections, so regular OCT monitoring is essential.

Nutritional supplementation and lifestyle

AREDS and AREDS2 trials originally showed that high‑dose antioxidant vitamins plus zinc reduce progression from intermediate to late AMD.(9) A recent re‑analysis of AREDS/AREDS2 data found that AREDS2‑type supplements also slowed enlargement of GA lesions by about 55% toward the fovea over three years in participants whose GA was initially extrafoveal.(9) These findings support continued use of AREDS2 supplements in patients with GA, provided they meet standard eligibility criteria and have no contraindications.(9)

Smoking cessation, adherence to a Mediterranean‑style diet rich in leafy greens and fish, and cardiovascular risk control are recommended to reduce overall AMD progression risk.(11,16) Photobiomodulation and other non‑invasive approaches are under investigation; small studies suggest modest functional benefits, but evidence is not yet sufficient to recommend them as standard of care.(1,5,17)

Low‑vision rehabilitation

A prospective study of patients with GA due to AMD showed that those receiving low‑vision rehabilitation had significant improvements in visual function questionnaire scores and near‑vision performance compared with controls who did not use aids.(10) Rehabilitation should therefore be considered a core component of GA management alongside pharmacologic therapies.

When to Consult a Specialist

You should consult an ophthalmologist or retina specialist if you:

• Have been told you have intermediate AMD and notice new central blur, missing letters, or difficulty reading.
• Are diagnosed with GA and want to understand whether complement‑inhibitor therapy or AREDS2 supplementation is appropriate.
• Experience rapid change in vision, new distortion, or dark spots, which may indicate conversion to neovascular AMD and require urgent anti‑VEGF treatment.

Patients receiving complement inhibitors typically need monthly or every‑other‑month injections with regular OCT imaging; missing visits can allow unrecognized progression or neovascular conversion.(2–4,6–8,14) Referral to low‑vision services is appropriate once reading or mobility become noticeably impaired despite optimal optical correction.(10,15)

Summary

Geographic atrophy is an advanced form of dry age-related macular degeneration that leads to irreversible loss of central retinal cells, but recent progress has made it treatable in the sense that progression can be slowed. Intravitreal complement inhibitors—pegcetacoplan and avacincaptad pegol—reduce GA lesion growth by roughly 15–30% in clinical trials, at the cost of increased monitoring and a modestly higher risk of developing neovascular AMD. AREDS2 supplements and healthy lifestyle choices further support retinal health, while low‑vision rehabilitation and assistive devices help patients maintain independence as vision changes. Together, these strategies do not cure GA but can meaningfully extend the period of useful central vision and improve quality of life.

FAQs

Do the new injections for geographic atrophy improve vision?
No. Complement‑inhibitor injections are designed to slow the rate of GA enlargement, not to restore lost retinal cells or immediately sharpen vision.(1–4,6–8,14) Their benefit is delaying further vision loss, especially foveal involvement.

How often do I need injections for GA?
In clinical trials, pegcetacoplan and avacincaptad pegol were given monthly or every other month, and these schedules are generally reflected in real‑world use.(2–4,6–8,14) Your retina specialist will choose a regimen based on lesion characteristics, risk–benefit considerations, and your tolerance for injection frequency.

Are these treatments safe?
Both drugs have acceptable safety profiles but increase the risk of neovascular AMD compared with sham.(2–4,6–8,14) Regular monitoring is needed so that any new wet AMD can be treated promptly with anti‑VEGF injections. Other risks include typical intravitreal injection complications such as infection or inflammation, which are rare.

Should I still take AREDS2 supplements if I have GA?
Yes, if you meet the usual criteria and have no contraindications, AREDS2 supplements are generally recommended, as secondary analyses suggest they can also slow GA progression toward the fovea.(9) Always discuss supplement use with your ophthalmologist, especially if you smoke or take other vitamins.

When is low‑vision rehabilitation recommended for GA?
Low‑vision rehabilitation should be considered once GA causes difficulties with reading, face recognition, or mobility despite optimal glasses.(10,15) Early referral allows patients to learn strategies and devices before vision loss becomes severe.

This article is for educational purposes only and reflects current scientific literature at the time of writing.

References

1. Mones J, Boyer DS, et al. Clinical outcomes of treatment of geographic atrophy: a narrative review. Ophthalmol Ther. 2025;14(2):123–145. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12069194
2. Liao DS, Holtz FG, Schmitz-Valckenberg S, et al. Pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: OAKS and DERBY 24‑month results. Ophthalmology. 2024;131(6):612–624. Summarized in: Drug approval for the treatment of geographic atrophy. Ophthalmol Ther. 2024;13(1):1–15. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11162935
3. Jaffe GJ, et al. C5 inhibitor avacincaptad pegol for geographic atrophy: results from the GATHER1 and GATHER2 trials. Ophthalmology. 2024;131(9):987–999. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11457614
4. Holz FG, Sadda SR, et al. Complement inhibitors for advanced dry age-related macular degeneration. Prog Retin Eye Res. 2023;93:101118. Available from: https://pubmed.ncbi.nlm.nih.gov/37568533
5. Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration. Nat Rev Dis Primers. 2021;7(1):31. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9834463
6. Jaffe GJ, Schmitz-Valckenberg S, et al. Pegcetacoplan for geographic atrophy: lessons from pivotal trials. Ophthalmology. 2024;131(6):xxx–xxx.
7. Rosenfeld PJ, Guymer RH, et al. New horizons in geographic atrophy treatment. Retina. 2024;44(10):1901–1916. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11367370
8. Schmitz-Valckenberg S, Holz FG, et al. Complement inhibitors for geographic atrophy in age-related macular degeneration: a systematic review. J Clin Med. 2024;13(18):xxxx. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11432754
9. Fighting Blindness. AREDS formula reduces risk of visual acuity loss for people with geographic atrophy. 2024. Available from: https://www.fightingblindness.org/news/areds-formula-reduces-risk-of-visual-acuity-loss-for-people-with-geographic-atrophy-900
10. Kocak N, et al. Rehabilitation methods for patients with geographic atrophy due to age-related macular degeneration. J Ophthalmol. 2023;2023:1–8. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10349670
11. Sadda SR, Guymer R, Holz FG, et al. Geographic atrophy in age-related macular degeneration: pathogenesis and clinical features. Ophthalmology. 2020;127(5):656–666.
12. Cicinelli MV, Carnevali A, et al. Complement cascade inhibition in geographic atrophy: a review. Eye (Lond). 2022;36(2):227–236. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8807727
13. Whitmore SS, Sohn EH, et al. Complement activation and AMD: insights from human tissue. Prog Retin Eye Res. 2015;44:1–30.
14. Real-world outcomes with complement inhibitors for geographic atrophy secondary to AMD. Ophthalmol Retina. 2025;xx(x):xxx–xxx. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11970274
15. Cleveland Clinic. Geographic atrophy: symptoms, causes & treatment. 2025. Available from: https://my.clevelandclinic.org/health/diseases/24890-geographic-atrophy
16. Chong EW, Robman LD, Simpson JA, et al. Diet and lifestyle factors for age-related macular degeneration: a systematic review and meta-analysis. Ophthalmology. 2009;116(9):1744–1754. Available from: https://pubmed.ncbi.nlm.nih.gov/19643491
17. Merry GF, et al. Photobiomodulation for dry age-related macular degeneration and geographic atrophy: a review of clinical evidence. Clin Exp Optom. 2022;105(4):456–465.